Biosev SA said its normalized net income for the fiscal fourth quarter ended March 31 came to a loss of 1.31 reais per share, compared with the S&P Capital IQ consensus estimate of a loss of 91 centavos per share.
The per-share result swung to a loss from the prior-year profit of 8 centavos.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 275.7 million reais, compared with income of 16.5 million reais in the year-earlier period.
The normalized profit margin fell to negative 18.9% from 1.9% in the year-earlier period.
Total revenue increased 71.2% on an annual basis to 1.46 billion reais from 852.5 million reais, and total operating expenses climbed 78.6% from the prior-year period to 1.37 billion reais from 767.8 million reais.
Reported net income came to a loss of 224.3 million reais, or a loss of 1.07 reais per share, compared to a loss of 1.02 billion reais, or a loss of 4.92 reais per share, in the prior-year period.
For the year, the company's normalized net income totaled a loss of 3.05 reais per share, compared with the S&P Capital IQ consensus normalized EPS estimate of a loss of 1.20 reais.
EPS was a loss of 73 centavos in the prior year.
Normalized net income was a loss of 630.7 million reais, compared with a loss of 149.8 million reais in the prior year.
Full-year total revenue rose 5.8% from the prior-year period to 4.51 billion reais from 4.27 billion reais, and total operating expenses grew 11.6% on an annual basis to 4.38 billion reais from 3.93 billion reais.
The company said reported net income totaled a loss of 501.9 million reais, or a loss of 2.43 reais per share, in the full year, compared with a loss of 1.47 billion reais, or a loss of 7.18 reais per share, the prior year.
As of June 9, US$1 was equivalent to 3.11 reais.
